Relvar Ellipta

Relvar Ellipta

Manufacturer:

GlaxoSmithKline

Distributor:

GlaxoSmithKline
Concise Prescribing Info
Contents
Per 100 mcg/25 mcg DPI Fluticasone furoate 100 mcg (equiv to 92 mcg), vilanterol trifenatate 25 mcg (equiv to 22 mcg). Per 200 mcg/25 mcg DPI Fluticasone furoate 200 mcg (equiv to 184 mcg), vilanterol trifenatate 25 mcg (equiv to 22 mcg)
Indications/Uses
Asthma in adults & adolescents ≥12 yr where use of long-acting β2-agonist & inhaled corticosteroid is appropriate including patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short-acting β2-agonists & those adequately controlled on both inhaled corticosteroid & long-acting β2-agonist. Adults w/ COPD w/ exacerbation history despite regular bronchodilator therapy.
Dosage/Direction for Use
Asthma Adult & adolescent ≥12 yr 1 inhalation of 100 mcg/25 mcg once daily. May consider 200 mcg/25 mcg if a higher dose is required in combination w/ a long-acting β2-agonist. COPD Adult ≥18 yr 1 inhalation of 100 mcg/25 mcg once daily. Moderate to severe hepatic impairment Max: 100 mcg/25 mcg.
Contraindications
Hypersensitivity to either fluticasone furoate or vilanterol. Severe milk-protein allergy.
Special Precautions
Not for the treatment of acute asthma symptoms. Discontinue use if paradoxical bronchospasm occur. Patient w/ severe CV disease; pulmonary TB, or chronic or untreated infections; history of DM. Possible systemic effects including Cushing's syndrome, cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in childn & adolescents, cataract & glaucoma. Visual disturbance. Hyperglycaemia. Increased incidence of pneumonia in patients w/ COPD & asthma. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Moderate to severe hepatic impairment. Pregnancy & lactation. Childn <12 yr. 200 mcg/25 mcg DPI: Not indicated for COPD.
Adverse Reactions
Headache; nasopharyngitis. Pneumonia, upper resp tract infection, bronchitis, flu, candidiasis of mouth & throat; oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia; abdominal pain; arthralgia, back pain, fractures; pyrexia, muscle spasm.
Drug Interactions
May weaken or antagonize effect w/ nonselective or selective β-blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir).
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AK10 - vilanterol and fluticasone furoate ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Relvar Ellipta 100 mcg/25 mcg DPI
Packing/Price
30 dose x 1's
Form
Relvar Ellipta 200 mcg/25 mcg DPI
Packing/Price
30 dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in